is prescribed to those with type 2 diabetes who have difficulty losing weight and staying on track with their daily habits. It is also available in the form of tablets, as well as the brand name Actos. It is important to note that it does not work in the same way as an antidiabetic medication, and is not suitable for individuals with diabetes that are not diabetic. Therefore, it is not recommended for individuals with diabetes that take Actos or any other diabetes medication. It is important to note that this drug should be used with caution in individuals with diabetes. Always follow your doctor's instructions when taking this medication.
As with any medication, the common side effects may include:
Less common but serious side effects may include:
While Actos is safe to use with other diabetes medications, it is important to note that it should only be used under the guidance of a healthcare professional. There is a possibility of interactions between Actos and other medications as well. The following medications can also interact with Actos:
It is important to inform your doctor about all the medications you are currently taking, as well as any you are currently taking.
It is also worth noting that Actos can cause an increased risk of heart attacks and strokes. It is important to avoid taking Actos and any other diabetes medications if you are currently taking any of the following medications:
For a complete list of medications, please refer to the patient information leaflet:
Do not take Actos if you have any of the following medical conditions:
The common side effects may include:
If you have any of the following medical conditions or are taking any medications, talk to your doctor before using Actos:
Actos can worsen side effects of certain medications, such as Actos. If you experience any serious side effects while using Actos, stop taking the medication and contact a doctor immediately.
Objective:To compare the effects of pioglitazone (GTX) with actos (ATO) on lipid metabolism in patients with type 2 diabetes mellitus (T2DM). The study was a double-blind, placebo-controlled study of patients with T2DM who were treated with pioglitazone or actos. Patients were randomly assigned to receive either pioglitazone or ACTOS either daily, once daily, or once weekly for 8 weeks. Baseline LDL-cholesterol (LDL-C) was measured at baseline, after 8 weeks of treatment, and at the end of treatment, and LDL-C was measured at baseline, after 8 weeks of treatment, and at the end of treatment. Patients were asked about their use of lipid-lowering medication (oral or injectable) and their response to the treatment. Change in HbA1c and glucose (HOMA-IR) at baseline, after 8 weeks of treatment and at the end of treatment were compared between patients treated with pioglitazone and ACTOS. Change in HbA1c at the end of treatment and at the end of treatment was compared between the two treatment arms. In addition, HbA1c and glucose were measured at baseline and during the end of treatment. A total of 855 patients (aged ≥50 years) were recruited from the community and the private medical and surgical clinics at the Giza University Teaching Hospital (Giza, Egypt) between July 2015 and June 2016. Baseline LDL-C (LDL-C) was measured at baseline, after 8 weeks of treatment, and at the end of treatment at 6 months after initiation of treatment. At the end of treatment, LDL-C was lower in patients treated with pioglitazone or actos at baseline. Change in HbA1c (HOMA-IR) was compared between the two treatment arms at the end of treatment at 6 months, after 8 weeks of treatment, and at the end of treatment at 6 months after initiation of treatment. Baseline and at the end of treatment were compared with at the end of treatment at 8 weeks after initiation of treatment. Change in glucose (HOMA-IR) was compared between the two treatment arms at the end of treatment and at the end of treatment. Baseline and at the end of treatment were compared with at the end of treatment at the end of treatment at the end of treatment (in patients with T2DM). Changes in HbA1c and HOMA-IR between baseline and during treatment were compared between the two treatment arms at the end of treatment (in patients with T2DM).
Results:After 8 weeks of treatment, patients who received pioglitazone daily (mean ± SD, 7.5 ± 1.6 mmol/mol,p< 0.001), who received ACTOS daily (mean ± SD, 5.5 ± 1.5 mmol/mol,= 0.005), or ACTOS once-a-day (mean ± SD, 1.7 ± 1.2 mmol/mol,= 0.053) were significantly more likely to have an LDL-C level <3% lower than patients who received ACTOS once-a-day (7.5 ± 1.6 mmol/mol,= 0.01). In addition, patients treated with pioglitazone or ACTOS at least once daily (at least once weekly) for 8 weeks had a lower percentage of patients who were treated with pioglitazone or ACTOS at least twice weekly (4.8 ± 1.8 %,= 0.003) and ACTOS at least once daily (4.3 ± 1.2 %,= 0.003) than patients treated with ACTOS at least once weekly (3.4 ± 1.3 %,= 0.003). There was no significant difference in HbA1c or glucose levels between the two treatment groups at 8 weeks after initiation of treatment (p = 0.096 and p = 0.097, respectively).
Conclusions:In patients with T2DM treated with pioglitazone or ACTOS, the mean LDL-C level was reduced in patients who received pioglitazone or ACTOS daily at least once daily for 8 weeks (3.5 ± 1.6 mmol/mol and 3.4 ± 1.2 mmol/mol, respectively,= 0.003) or in patients who received ACTOS once-a-day (3.
Actos is a medication used to lower the risk of bladder cancer. It is an inhibitor of a cellular enzyme that is responsible for the production of dihydrotestosterone (DHT), a hormone that can lead to a number of physical and emotional complications. By decreasing DHT levels, Actos can help reduce the risk of developing bladder cancer and other cancers.
Actos contains the active ingredient pioglitazone as its first-generation isomer. This drug belongs to a class of medications called thiazolidinediones. It works by blocking the enzyme type II 5-alpha-reductase, which is responsible for the production of testosterone in the body. This action prevents DHT from binding to the receptor, which then inhibits the conversion of testosterone to DHT. By blocking the enzyme type II 5-alpha-reductase, Actos can slow down the production of DHT and, thus, reducing the risk of developing bladder cancer.
This medication is available in different forms such as tablets, oral solution, extended-release tablets, or injectable solution. The dosage of this drug varies depending on the individual’s health condition, age, and other medications being taken. The most common dosage of Actos is one 10 mg tablet taken once a day. The dosage of Actos can also be increased by up to 25 mg or decreased by 5 mg based on the response to the medication.
Actos is not suitable for people who have had bladder cancer or have a history of bladder cancer. It is also not suitable for people who are taking certain medications that have been linked with bladder cancer.
Actos is used to reduce the risk of developing bladder cancer by inhibiting the enzyme type II 5-alpha-reductase that is responsible for the production of testosterone. By blocking the enzyme type II 5-alpha-reductase, Actos can reduce the risk of developing bladder cancer and other cancers.
Actos may cause side effects, although not everyone experiences them. Common side effects of Actos include increased frequency of sexual activity and decreased appetite. It may also be more likely to cause an irregular heartbeat, seizures, and vision changes. More serious side effects may include high blood pressure, abnormal liver enzymes (such as liver enzyme tests), and kidney problems.
Actos can cause side effects, though not everyone experiences them. It may also cause an irregular heartbeat, seizures, and vision changes.
Do not take Actos if you:
Do not take Actos if you have ever had an allergic reaction to pioglitazone, any of the ingredients in Actos, or any of the inactive ingredients in Actos.
Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider may need to monitor you for side effects to check if Actos is safe for you.
Take Actos exactly as prescribed by your healthcare provider. Follow the dosage instructions on the packaging. It is important not to skip doses or stop taking the medicine too early or too late. Taking more than the recommended dose of Actos may increase the risk of serious side effects.
The maximum recommended dose of Actos is one 10 mg tablet taken once a day. It may be increased by up to 25 mg or decreased by 5 mg based on the response to the medication. Your healthcare provider may also adjust your dose based on your symptoms and other medical conditions.
Store Actos at room temperature, away from light and moisture. Keep Actos out of the reach of children. Keep all medicines out of the reach of pets.
Lactose intolerance is a common condition in children and adolescents, affecting around 5% to 20% of the adult population. However, there are limited studies in the literature on its prevalence in children and adolescents, and only a few studies have investigated the prevalence of lactose intolerance in adults. The aim of this study was to explore the prevalence of lactose intolerance in adults, and to investigate the associated factors in relation to age and sex. A prospective, cross-sectional, case-control study was conducted in 14 clinical sites in Pakistan (PVT, Jhelum, Khanewal, Hainistan and Lahore). The study population included patients with lactose intolerance. They were randomly assigned to receive a lactose-free diet for 4 weeks or a no-lactose-free diet for 3 months.
We included patients aged 14 to 30 years with a diagnosis of lactose intolerance. Patients were excluded if they: 1) had severe hepatic or renal disease, 2) had cirrhosis, 3) had lactose intolerance within the previous 3 months, 4) had an active myeloma or malignant neoplasia within the past 12 months, and 5) were taking any medications that may affect lactose metabolism. Exclusion criteria included a diagnosis of lactose intolerance in the past 6 months; a history of or drug-induced diarrhea; a history of or immunosuppressive therapy within the past 6 months; and a history of an allergy to lactose or any of the listed ingredients.
The population comprised of patients with lactose intolerance in the 14 clinical sites (PVT, Jhelum, Khanewal, Hainistan and Lahore). All the sites were selected from among patients who were diagnosed with lactose intolerance by their doctors. They had a history of lactose intolerance in the past 3 months, and were diagnosed with lactose intolerance within the previous 3 months. The sites included the following: VT (PVT); Jhelum (Hainistan); Khanewal (Hikabad); and the sites in the other four regions of Pakistan (Bikolam, Quetta, Sindh, Pakotr, and Peshawar). The sites included the following: VT (PVT); Jhelum (Hainistan); Khanewal (Hikabad); Quetta (Sindh); and the sites in the other four regions of Pakistan (Bikolam, Quetta, Sindh, Pakotr, and Peshawar).
The statistical analysis plan was designed using R version 3.4.0. Statistical analyses were performed using the IBM SPSS® Statistics software program (IBM Corp., Armonk, NY, United States). Qualitative variables were expressed by frequency and percentage, and quantitative variables were expressed by frequency and percentage, and frequency and percentage. The Chi-square test was used for categorical variables. The χ2 test was used for continuous variables, the Student’st-test was used for numerical data, and the Wilcoxon rank-sum test was used for proportions. The study was approved by the Institutional Review Board of PKRU Institute of Medical Sciences and Alli University. The study was registered on IDICID website.
The study population comprised of patients with lactose intolerance in the 14 clinical sites. The prevalence of lactose intolerance was higher in patients with lactose intolerance compared to patients without lactose intolerance. The prevalence of lactose intolerance was higher in patients with lactose intolerance compared to those without lactose intolerance.
Stade de France Pharmacy